Natco Pharma shares rallied as much as 6.4 percent in morning Monday after the Mekaguda facility received zero observations from the US health regulator.
"....announce successful completion of regulatory inspection from the United States Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) facility in Mekaguda Village, Hyderabad," the pharma company said in its filing.
The inspection by USFDA was conducted during the period February 12-16, 2018.
"The regulatory audit resulted in zero observations (no form 483 issued)," Natco said.
Meanwhile, the drug firm earlier in the month reported a 11.54 percent rise in its consolidated profit after tax at Rs 217.4 crore for the quarter ended December 2017.
Consolidated total revenues during the quarter declined to Rs 573.6 crore from Rs 685.1 crore in the same period a year ago.